Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ)
Tonghua, CN
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is a Chinese pharmaceutical firm actively involved in the full spectrum of drug development, from research and development to manufacturing and sales. Its therapeutic focus primarily encompasses key areas such as rheumatism, digestive health, oncology, and gynecology. The company boasts a comprehensive and diverse product portfolio. This includes a wide array of traditional Chinese medicines (TCMs), addressing conditions like gynecological issues, rheumatic and bone pain, urological disorders, detoxification needs, cardiovascular and cerebral health, digestive and respiratory ailments, diabetes, and pediatric concerns. Beyond TCMs, it also develops and markets anti-tumor drugs, both prescription and over-the-counter (OTC) medications, and conventional Western pharmaceuticals. These products are available in multiple dosage forms, including capsules, tablets, injections, and liquid preparations. Established in 1990, the company is headquartered in Tonghua, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09% | +1.18% | -3.14% | +0.70% | -15.00% | -15.71% | +13.02% | +326.70% | +402.60% | +82.73% | +162.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-11.5% Q1'26: +0.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-33.3% Q1'26: -21.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.2% Q1'26: +12.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.7% Q1'26: +10.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.6% Q1'26: +2.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-8.9% ★ Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×9.65× Q1'26: 16.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 845.6K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 60.8K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 27.0K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 3.00M | 0.06% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 69.7K | 0.29% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 41.1K | 0.10% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 3.38M | 0.05% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 22.4K | 0.39% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 217.9K | 0.06% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.8K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hailong Zhang | Executive Vice President | — | male |
| Huan Wang | Deputy GM & Non-Independent Director | — | male |
| Jun Yu | Deputy GM & Chief Financial Officer | — | male |
| Lan Geng | Accounting Supervisor | — | — |
| Weilin Jia | Board Secretary | — | male |
| Xiaolang Yu | Deputy General Manager | — | male |
| Yu Jing | Deputy GM & Non-Independent Director | — | male |
| Yufu Zhang | GM & Chairman | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000766.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
